Piper Jaffray Companies dropped coverage on shares of BridgeBio Pharma (NASDAQ:BBIO) in a research report report published on Friday, TipRanks reports.

Other equities research analysts have also recently issued research reports about the company. Goldman Sachs Group started coverage on BridgeBio Pharma in a report on Monday, July 22nd. They set a buy rating and a $42.00 target price on the stock. Svb Leerink started coverage on BridgeBio Pharma in a report on Monday, July 22nd. They set an outperform rating and a $34.00 target price on the stock. Raymond James started coverage on BridgeBio Pharma in a report on Friday, July 26th. They set an outperform rating and a $36.00 target price on the stock. Jefferies Financial Group started coverage on BridgeBio Pharma in a report on Monday, July 22nd. They set a buy rating and a $38.00 target price on the stock. Finally, BMO Capital Markets started coverage on BridgeBio Pharma in a report on Monday, July 22nd. They set an outperform rating and a $49.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus price target of $40.13.

Shares of NASDAQ:BBIO opened at $18.63 on Friday. The company’s fifty day moving average is $23.39. BridgeBio Pharma has a one year low of $17.61 and a one year high of $32.94.

Several institutional investors have recently modified their holdings of the business. Kohlberg Kravis Roberts & Co. L.P. purchased a new position in shares of BridgeBio Pharma during the 2nd quarter worth $995,211,000. Viking Global Investors LP purchased a new position in shares of BridgeBio Pharma during the 2nd quarter worth $717,968,000. American International Group Inc. purchased a new position in shares of BridgeBio Pharma during the 2nd quarter worth $181,569,000. Perceptive Advisors LLC purchased a new position in shares of BridgeBio Pharma during the 2nd quarter worth $180,868,000. Finally, Aisling Capital Management LP purchased a new position in shares of BridgeBio Pharma during the 2nd quarter worth $103,449,000. 85.32% of the stock is currently owned by institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Featured Story: Trading Options- What is a Strangle?

Analyst Recommendations for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.